Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer

The association of polymorphisms in folate-metabolizing genes with response to adjuvant... Background Colorectal cancer (CRC) is one of the major health issues worldwide. 5-Fluorouracil (5-FU) is a cornerstone of chemotherapy for CRC and the major targets of 5-FU are folate-metabolizing enzymes. Methods A total of 103 CRC patients with complete clinical data were included in this prospective cohort study. Genotyp- ing was performed using polymerase chain reaction (PCR) followed by sequencing. Using Kaplan–Meier curves, log-rank tests, and Cox proportional hazard models, we evaluated associations between functional polymorphisms in four genes MTHFR (1298A>C and 677C>T), DPYD (496A>G and 85T>C), DHFR 19 bp del, and MTR (2756 A>G) with disease- free survival (DFS). Results The minor allele frequencies of MTHFR 1298A>C, MTHFR 677C>T, DPYD 496A>G, DPYD 85T>C, DHFR 19 bp del, and MTR 2756 A>G were 0.364, 0.214, 0.116, 0.209, 0.383, and 0.097, respectively. CRC patients carrying the homozygous GG genotype in DPYD 496A>G had 4.36 times shorter DFS than wild-type AA carriers, (DFS vs : 8.0 ± 4 GG AA vs 69.0 ± 10 months; HR 4.36, 95% CI 1.04–18; p = 0.04). Moreover, female carriers of homozygous CC genotype of DPYD 85T>C had shorter DFS compared to either heterozygous or wild-type genotypes, and were 12.7 times shorter than wild- type TT carriers (DFS http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Chemotherapy and Pharmacology Springer Journals

The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer

Download PDF
7 pages

Loading next page...
 
/lp/springer_journal/the-association-of-polymorphisms-in-folate-metabolizing-genes-with-9UU04wxoCY
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Pharmacology/Toxicology; Cancer Research
ISSN
0344-5704
eISSN
1432-0843
DOI
10.1007/s00280-018-3608-6
Publisher site
See Article on Publisher Site

Abstract

Background Colorectal cancer (CRC) is one of the major health issues worldwide. 5-Fluorouracil (5-FU) is a cornerstone of chemotherapy for CRC and the major targets of 5-FU are folate-metabolizing enzymes. Methods A total of 103 CRC patients with complete clinical data were included in this prospective cohort study. Genotyp- ing was performed using polymerase chain reaction (PCR) followed by sequencing. Using Kaplan–Meier curves, log-rank tests, and Cox proportional hazard models, we evaluated associations between functional polymorphisms in four genes MTHFR (1298A>C and 677C>T), DPYD (496A>G and 85T>C), DHFR 19 bp del, and MTR (2756 A>G) with disease- free survival (DFS). Results The minor allele frequencies of MTHFR 1298A>C, MTHFR 677C>T, DPYD 496A>G, DPYD 85T>C, DHFR 19 bp del, and MTR 2756 A>G were 0.364, 0.214, 0.116, 0.209, 0.383, and 0.097, respectively. CRC patients carrying the homozygous GG genotype in DPYD 496A>G had 4.36 times shorter DFS than wild-type AA carriers, (DFS vs : 8.0 ± 4 GG AA vs 69.0 ± 10 months; HR 4.36, 95% CI 1.04–18; p = 0.04). Moreover, female carriers of homozygous CC genotype of DPYD 85T>C had shorter DFS compared to either heterozygous or wild-type genotypes, and were 12.7 times shorter than wild- type TT carriers (DFS

Journal

Cancer Chemotherapy and Pharmacology – Springer Journals

Published: May 29, 2018

References

  • Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set
    O’Connell, MJ; Campbell, ME; Goldberg, RM; Grothey, A; Seitz, JF; Benedetti, JK; Andre, T; Haller, DG; Sargent, DJ
  • Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial
    Andre, T; Boni, C; Navarro, M; Tabernero, J; Hickish, T; Topham, C; Bonetti, A; Clingan, P; Bridgewater, J; Rivera, F; Gramont, A
  • Folic acid-metabolizing enzymes regulate the antitumor effect of 5-fluoro-2′-deoxyuridine in colorectal cancer cell lines
    Tsukihara, H; Tsunekuni, K; Takechi, T
  • Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes
    Focaccetti, C; Bruno, A; Magnani, E; Bartolini, D; Principi, E; Dallaglio, K; Bucci, EO; Finzi, G; Sessa, F; Noonan, DM; Albini, A
  • Polymorphisms of folate metabolism-related genes and survival of patients with colorectal cancer in the Korean population
    Jang, MJ; Kim, JW; Jeon, YJ; Chong, SY; Hong, SP; Hwang, SG; Oh, D; Cho, YK; Ji, YG; Kim, NK
  • MTHFR (C677T) polymorphisms and stage III colon cancer: response to therapy
    Wisotzkey, JD; Toman, J; Bell, T; Monk, JS; Jones, D
  • Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
    Ruzzo, A; Graziano, F; Loupakis, F; Rulli, E; Canestrari, E; Santini, D; Catalano, V; Ficarelli, R; Maltese, P; Bisonni, R; Masi, G; Schiavon, G; Giordani, P; Giustini, L; Falcone, A; Tonini, G; Silva, R; Mattioli, R; Floriani, I; Magnani, M
  • The 677C > T (rs1801133) polymorphism in the MTHFR gene contributes to colorectal cancer risk: a meta-analysis based on 71 research studies
    Teng, Z; Wang, L; Cai, S; Yu, P; Wang, J; Gong, J; Liu, Y
  • Association between MTHFR polymorphisms and overall survival of colorectal cancer patients in Northeast China
    Zhu, L; Wang, F; Hu, F; Wang, Y; Li, D; Dong, X; Cui, B; Zhao, Y
  • Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives
    Fogli, S; Caraglia, M
  • Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients
    Kristensen, MH; Pedersen, PL; Melsen, GV; Ellehauge, J; Mejer, J
  • Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity
    Amstutz, U; Froehlich, TK; Largiadèr, CR
  • Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients
    Gross, E; Busse, B; Riemenschneider, M; Neubauer, S; Seck, K; Klein, H-G; Kiechle, M; Lordick, F; Meindl, A
  • Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304)
    Ulrich, CM; Rankin, C; Toriola, AT; Makar, KW; Altug-Teber, O; Benedetti, JK; Holmes, RS; Smalley, SR; Blanke, CD; Lenz, HJ
  • A functional 19-base pair deletion polymorphism of dihydrofolate reductase (DHFR) and risk of breast cancer in multivitamin users
    Xu, X; Gammon, MD; Wetmur, JG; Rao, M; Gaudet, MM; Teitelbaum, SL; Britton, JA; Neugut, AI; Santella, RM; Chen, J
  • Molecular genetic analysis of the human dihydrofolate reductase gene: relation with plasma total homocysteine, serum and red blood cell folate levels
    Gellekink, H; Blom, HJ; Linden, IJ; Heijer, M
  • MTR and MTRR polymorphisms, dietary intake, and breast cancer risk
    Shrubsole, MJ; Gao, Y-T; Cai, Q; Shu, XO; Dai, Q; Jin, F; Zheng, W
  • The 2756A > G variant in the gene encoding methionine synthase: its relation with plasma homocysteine levels and risk of coronary heart disease in a Dutch case-control study
    Klerk, M; Lievers, KJ; Kluijtmans, LA; Blom, HJ; Heijer, M; Schouten, EG; Kok, FJ; Verhoef, P
  • Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity
    Offer, SM; Fossum, CC; Wegner, NJ; Stuflesser, AJ; Butterfield, GL; Diasio, RB
  • Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity
    Amstutz, U; Froehlich, TK; Largiader, CR
  • Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer
    Uetake, H; Ichikawa, W; Takechi, T; Fukushima, M; Nihei, Z; Sugihara, K
  • Regulation of dihydropyrimidine dehydrogenase in colorectal cancer
    Johnston, SJ; Ridge, SA; Cassidy, J; McLeod, HL
  • Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer
    Kidd, EA; Yu, J; Li, X; Shannon, WD; Watson, MA; McLeod, HL
  • Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy
    Kleibl, Z; Fidlerova, J; Kleiblova, P; Kormunda, S; Bilek, M; Bouskova, K; Sevcik, J; Novotny, J
  • Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer
    Zhao, J; Li, W; Zhu, D; Yu, Q; Zhang, Z; Sun, M; Cai, S; Zhang, W
  • MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer
    Afzal, S; Jensen, SA; Vainer, B; Vogel, U; Matsen, JP; Sorensen, JB; Andersen, PK; Poulsen, HE
  • Methylenetetrahydrofolate reductase polymorphism (677 C > T) predicts long time to progression in metastatic colon cancer treated with 5-fluorouracil and folinic acid
    Castillo-Fernandez, O; Santibanez, M; Bauza, A; Calderillo, G; Castro, C; Herrera, R; Serrano, A; Arrieta, O; Herrera, LA
  • Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and fluorouracil-based treatment in Taiwan colorectal cancer
    Wu, NC; Su, SM; Lin, TJ; Chin, J; Hou, CF; Yang, JY; Liu, WS; Chang, LC
  • Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy
    Cohen, V; Panet-Raymond, V; Sabbaghian, N; Morin, I; Batist, G; Rozen, R
  • Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer
    Etienne-Grimaldi, MC; Francoual, M; Formento, JL; Milano, G
  • Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis
    Jennings, BA; Kwok, CS; Willis, G; Matthews, V; Wawruch, P; Loke, YK
  • Beyond thymidylate synthase and dihydrofolate reductase: impact of non-coding microRNAs in anticancer chemoresistance
    Ju, J